Alto Neuroscience, Inc.
ANRO
NYSE·Healthcare·Biotechnology·Mkt cap $1.2B
$35.13
▼ -3.22%
P/E
-14.17
Mkt Cap
$1.2B
52-Wk Range
$3.41–$37.48
52-Week Range
$3.41 - $37.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 805.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-powered biomarker platform for patient identification and treatment matching
- Novel mechanism of action drug candidates addressing underserved psychiatric indications
- Pharmacodynamically synergistic drug combinations leveraging multiple therapeutic targets
- Early-stage pipeline with multiple shots on goal across high-prevalence mental health disorders
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of clinical trials and potential FDA approvals for pipeline candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+75.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ANRO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.65 vs -$0.73 consensus (+11.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 13, 2026
vs Industry
How ANRO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related